Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients

Akihiro Kitadate, Hiroki Kohiyashi, Yoshiaki Abe, Kentaro Narita, Daisuke Miura, Masami Takeuchi, and Kosei Matsue
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
Correspondence: AKIHIRO KITADATE - akihiro_kitadate@yahoo.co.jp
Supplementary Figure Legends

Figure S1. Analysis of CD38-positive Tregs after daratumumab treatment using CD38 multi-epitope antibody.

A. Flow cytometry analysis for circulating CD38⁺ Tregs using CD38 multi-epitope (CD38ME) antibody (Cytognos). The percentages of the gated subsets are shown.

B. Shown are representative example of CD38⁺ Tregs before and 4 weeks after daratumumab treatment. The percentages of the gated subsets are shown.

C. Difference between the frequency of the CD38⁻ Tregs before and 4 weeks after daratumumab treatment.

Y-axis: absolute numbers of Treg cells (cells/µL).
Figure S1

A

CD45-ECD

SSC

CD45+ 30.6%

CD25^high^CD127^dim^ 6.9%

CD127-PC7

CD38ME-FITC

CD4-PE

CD4+ 35.8%

CD38+ 18.2%

SSC

CD4-PE

CD38ME-FITC

B

Before treatment

After treatment

CD38+ 12.6%

CD38+ 0.6%

CD4-PE

CD38ME-FITC

C

Before After

0 10 20 30

CD38^+^ Tregs

Absolute number (cells/µl)

Before After

0 10 20 30